Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sweden

Europe needs to refocus its drug anti-counterfeiting measures

This article was originally published in Scrip

Executive Summary

Counterfeit medicines have been big news in Europe over the past two months. The pharmaceutical industry, the World Health Organization and the European Parliament have been vociferously expounding on the success and progress of various initiatives aimed at preventing the emergence of fake medicinal products in the legitimate supply chain. These are welcome and laudable actions, aimed at protecting human health, but are they focusing on the right target?

Table

View full table

Topics

Tags:
Sweden
Latest Headlines

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

GSK Looks Forward To RSV Vaccine Competition

Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously

See All
UsernamePublicRestriction

Register

SC008636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By